Orchid Pharma has historically prioritized reinvesting its operational capital into debt reduction, plant modernization, manufacturing capabilities, and research and development initiatives following its corporate restructuring and turnaround. Consequently, the company has largely focused on balance sheet strengthening rather than regular cash dividend distributions to common equity shareholders.